Aidan Aflaki Vosooghi

Mr. Aidan Aflaki Vosooghi

Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Hepatology
Verified
Journal Article
Closed access
CHChristine C. Hsu
Christine C. Hsu
JDJennifer L. Dodge
Jennifer L. Dodge
EWEthan Weinberg
Ethan Weinberg
GIGene Im
Gene Im
JKJimin Ko
Jimin Ko
BLBrian P. Lee
Brian P. Lee
Background: Early liver transplantation for alcohol-associated hepatitis is controversial in part because patients may recover, and obviate the need for liver transplantation. Methods: In this retrospective study among 5 ACCELERATE-AH sites, we randomly sampled patients evaluated and then declined for liver transplantation for alcohol-associated hepatitis. All had Model of End-Stage Liver Disease (MELD) >20 and <6 months of abstinence. Recompensation was defined as MELD <15 without variceal bleeding, ascites, or overt HE requiring treatment. Multilevel mixed effects linear regression was used to calculate probabilities of recompensation; multivariable Cox regression was used for mortality analyses. Results: Among 145 patients [61% men; median abstinence time and MELD-Na was 33 days (interquartile range: 13–70) and 31 (interquartile range: 26–36), respectively], 56% were declined for psychosocial reasons. Probability of 30-day, 90-day, 6-month, and 1-year survival were 76% (95% CI, 68%–82%), 59% (95% CI, 50%–66%), 49% (95% CI, 40%–57%), and 46% (95% CI, 37%–55%), respectively. Probability of 1-year recompensation was low at 10.0% (95% CI, 4.5%–15.4%). Among patients declined because of clinical improvement, 1-year probability of recompensation was 28.0% (95% CI, 5.7%–50.3%). Among survivors, median MELD-Na at 30 days, 90 days, and 1-year were 29 (interquartile range: 22–38), 19 (interquartile range : 14–29), and 11 (interquartile range : 7–17). Increased MELD-Na (adjusted HR: 1.13, p<0.001) and age (adjusted HR: 1.03, p<0.001) were associated with early (≤90 d) death, and only history of failed alcohol rehabilitation (adjusted HR: 1.76, p=0.02) was associated with late death. Conclusions: Liver recompensation is infrequent among severe alcohol-associated hepatitis patients declined for liver transplantation. Higher MELD-Na and age were associated with short-term mortality, whereas only history of failed alcohol rehabilitation was associated with long-term mortality. The distinction between survival and liver recompensation merits further attention.

21 January 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
BLBrian P. Lee
Brian P. Lee
GCGiuseppe Cullaro
Giuseppe Cullaro
AVAidan Aflaki Vosooghi
Aidan Aflaki Vosooghi
FYFrederick Yao
Frederick Yao
SPSarjukumar Panchal
Sarjukumar Panchal
NMNadim Mahmud
Nadim Mahmud

29 November 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
EJEmily Johnson
Emily Johnson
MBMaria Bolshakova
Maria Bolshakova
AVAidan Aflaki Vosooghi
Aidan Aflaki Vosooghi
CLChun Nok Lam
Chun Nok Lam
RTRebecca Trotzky-Sirr
Rebecca Trotzky-Sirr
TSTodd Schneberk
Todd Schneberk
In the wake of COVID-19, morbidity and mortality due to Opioid Use Disorder (OUD) is beginning to emerge as a second wave of deaths of despair. Medication assisted treatment (MAT) for opioid use disorder MAT delivered by Emergency Medicine (EM) providers can decrease mortality due to OUD; however, there are numerous cited barriers to MAT delivery. We examined the impact of MAT training on these barriers among EM residents in an urban, tertiary care facility with a large EM residency. Training included the scripted and standardized content from the Provider Clinical Support System curriculum. Residents completed pre- and post-training surveys on knowledge, barriers, and biases surrounding OUD. We performed Wilcoxon matched-pairs signed-ranks test to detect statistical differences. Of 74 residents, 49 (66%) completed the pre-training survey, and 34 (69%) of these completed the follow-up survey. Residents reported improved preparedness to treat aspects of OUD across all areas queried, reported decreased perception of barriers to providing MAT, and increased comfort prescribing naloxone, counseling patients, prescribing buprenorphine, and treating opioid withdrawal. A didactic training on MAT was associated with residents reporting improved comfort providing buprenorphine and naloxone. As the wake of morbidity and mortality from both COVID and OUD continue to increase, programs should offer dedicated training on MAT.

29 March 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
EJEmily Johnson
Emily Johnson
SASarah Axeen
Sarah Axeen
AVAidan Aflaki Vosooghi
Aidan Aflaki Vosooghi
CLChun Nok Lam
Chun Nok Lam
Ricky BluthenthalRicky Bluthenthal
Ricky Bluthenthal
TSTodd Schneberk
Todd Schneberk
The COVID-19 pandemic led to disruptions in care for vulnerable patients, in particular patients with opioid use disorder (OUD). We aimed to examine OUD-related ED visits before and during the COVID-19 pandemic and determine if patient characteristics for OUD-related ED visits changed in the context of the pandemic. We examined all visits to the three public safety net hospital EDs in Los Angeles County from April 2019 to February 2021. We performed interrupted time series analyses examining OUD-related ED visits from Period 1, April 2019 to February 2020, compared with Period 2, April 2020 to February 2021, by race/ethnicity and payor group. We considered OUD-related ED visits as those which included any of the following: discharge diagnosis related to OUD, patients administered buprenorphine or naloxone while in the ED, and visits where a patient was prescribed buprenorphine or naloxone on discharge. There were 5919 OUD-related ED visits in the sample. OUD-related visits increased by 4.43 (2.82–6.03) per 1000 encounters from the pre-COVID period (9.47 per 1000 in February 2020) to the COVID period (13.90 per 1000 in April 2020). This represented an increase of 0.41/1000 by white patients, 0.92/1000 by black patients, and 1.83/1000 by Hispanic patients. We found increases in OUD-related ED visits among patients with Medicaid managed care of 2.23/1000 and in LA County safety net patients by 3.95/1000 ED visits. OUD-related ED visits increased during the first year of the COVID pandemic. These increases were significant among black, white, and Hispanic patients, patients with Medicaid managed care, and LA County Safety net patients. These data suggest public emergency departments served as a stopgap for patients suffering from OUD in Los Angeles County during the pandemic and can be utilized to guide preventative interventions in vulnerable populations.

28 April 2025 in Cancer Medicine
Verified
Journal Article
Open access
AMAditya Mahadevan
Aditya Mahadevan
AVAidan Aflaki Vosooghi
Aidan Aflaki Vosooghi
JAJagmeet Arora
Jagmeet Arora
JJJeffrey Jones
Jeffrey Jones
MMMaziar Moslehyazdi
Maziar Moslehyazdi
WCWarren Allen Chow
Warren Allen Chow
Background: The impact of baseline cardiovascular disease (CVD) on survival in patients undergoing immune checkpoint inhibitor (ICI) therapy is not well understood. Therefore, we sought to determine the relationship between baseline CVD on mortality in patients undergoing ICI monotherapy or combination therapy. Methods: Using TriNetX, a global database of over 120 million patients, we identified 27,820 patients with pre‐existing cardiovascular disease prior to starting ICI monotherapy and an equal number of corresponding matched controls. Results: Systolic heart failure (HR: 1.38, 95% CI: 1.29–1.48), diastolic heart failure (HR: 1.34, 95% CI: 1.27–1.42), and atrial fibrillation/flutter (HR: 1.24, 95% CI: 1.19–1.29) had the greatest associations with mortality across ICI monotherapy. Conclusion: Future trials of patients initiating ICI therapy should capture these baseline values to guide risk assessment, pretreatment optimization, and surveillance strategies prior to treatment initiation.

20 October 2026 in JACC: Cardiooncology
Verified
Journal Article
Open access
AIAnis Ismail
Anis Ismail
AVAlexi Vasbinder
Alexi Vasbinder
BBBobby Bobby
Bobby Bobby
MBMcKenna de Bever
McKenna de Bever
AVAidan Aflaki Vosooghi
Aidan Aflaki Vosooghi
SHSalim S. Hayek
Salim S. Hayek